What is Human Longevity?
Established in 2013, Human Longevity, Inc. (HLI) operates at the intersection of biotechnology and preventative healthcare. The company is recognized as a global leader in the pursuit of longevity medicine, utilizing proprietary genomic sequencing and clinical data to provide actionable health insights. By integrating complex biological data with clinical expertise, HLI aims to shift the medical paradigm from reactive treatment to proactive, personalized health management. The firm's market position is reinforced by its extensive history of strategic partnerships with major life sciences entities, enabling it to maintain a competitive edge in the rapidly evolving biotech landscape.
How much funding has Human Longevity raised?
Human Longevity has raised a total of $370.8M across 5 funding rounds:
Series A
$80M
Series B
$220M
Other Financing Round
$30M
Debt
$1M
Series B
$39.8M
Series A (2014): $80M with participation from Illumina, Draper Fisher Jurvetson (DFJ), Daniel Curran, Synthetic Genomics, and Celgene
Series B (2016): $220M led by Celgene, GE Ventures, and Illumina
Other Financing Round (2019): $30M supported by Emerging Technology Partners
Debt (2020): $1M featuring PPP
Series B (2024): $39.8M backed by TVM Capital Healthcare Partners, Emerging Technology Partners, and Panacea Ventures
Key Investors in Human Longevity
TVM Capital Healthcare Partners
TVM Capital Healthcare is an emerging markets-focused healthcare private equity investment firm. The organization invests growth capital and focuses on specialized healthcare services, digital health solutions, pharmaceuticals, medical devices, and diagnostics.
Emerging Technology Partners
ETP Capital is a life sciences-focused investment fund founded in 2000, dedicated to providing capital and support for the development and commercialization of innovative diagnostic and therapeutic products in the biomedical industry.
Panacea Ventures
Panacea Capital is a global healthcare venture fund focused on driving innovation in the biotech sector, with a portfolio dedicated to transforming lives through investments in life sciences and regenerative medicine.
What's next for Human Longevity?
The recent capital allocation is strategically earmarked for aggressive growth initiatives. Human Longevity plans to leverage these funds to deepen its penetration within the U.S. market while simultaneously executing a planned expansion into the Kingdom of Saudi Arabia and Southeast Asia. This geographic diversification is intended to scale the company's precision medicine platform to a broader global demographic, addressing the rising demand for high-fidelity health diagnostics and personalized longevity protocols. As the company matures, the focus remains on scaling its operational infrastructure to support long-term clinical outcomes and sustainable commercial growth.
See full Human Longevity company page
